News summary

Annovis’ Phase 3 Alzheimer’s trial gets second safety clearance

Source: Longevity Technology • Published: 18 Nov 2026, 13:36

Summarized by Masters of Longevity from Longevity Technology.

A DSMB issued a second positive safety recommendation for DUET-AD.

Annovis’ Phase 3 Alzheimer’s trial gets second safety clearance
Key Takeaways
  • A DSMB reviewed interim safety data and recommended continuation.
  • DUET‑AD is testing oral buntanetap in early Alzheimer’s patients.
  • This second clearance allows dosing but does not show efficacy.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.